Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ranitidine HCL

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 23Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Allows Reformulated Ranitidine Back On The Market
    FDA Allows Reformulated Ranitidine Back On The Market

    28 Nov 2025

    // RAPS

    https://www.raps.org/news-and-articles/news-articles/2025/11/fda-allows-reformulated-ranitidine-back-on-the-mar

    RAPS
    28 Nov 2025
    Share Share
    FDA Approves SMS Pharma's Reformulated Ranitidine
    FDA Approves SMS Pharma's Reformulated Ranitidine

    27 Nov 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/drug-approval/sms-pharmaceuticals-associate-company-receives-fda-approval-for-reformulated-ranitidine-18367

    INDPHARMAPOST
    27 Nov 2025
    Share Share
    DCGI Directs Drug Controllers to Carcinogenic in Ranitidine
    DCGI Directs Drug Controllers to Carcinogenic in Ranitidine

    29 Jul 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/monitor-presence-of-potentially-carcinogenic-chemical-in-ranitidine-dcgi-to-drug-controllers/articleshow/122971132.cms

    ECONOMICTIMES
    29 Jul 2025
    Share Share
    Ranitidine ban deferred despite cancer concerns
    Ranitidine ban deferred despite cancer concerns

    01 May 2025

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/ranitidine-ban-deferred-despite-cancer-concerns/articleshow/120776186.cms

    ECONOMICTIMES
    01 May 2025
    Share Share
    A second Zantac cancer trial ends with hung jury
    A second Zantac cancer trial ends with hung jury

    19 Sep 2024

    // REUTERS

    https://www.reuters.com/legal/second-zantac-cancer-trial-ends-with-hung-jury-2024-09-18/

    REUTERS
    19 Sep 2024
    Share Share
    GSK settles two California lawsuits related to heartburn drug Zantac
    GSK settles two California lawsuits related to heartburn drug Zantac

    18 Sep 2024

    // REUTERS

    https://www.reuters.com/legal/gsk-settles-two-california-lawsuits-related-heartburn-drug-zantac-2024-09-18/

    REUTERS
    18 Sep 2024
    Share Share